Non-invasive Electrical Stimulation for the Central and Peripheral Nervous System

Adam Williamson Senior Research Team Leader International Clinical Research Center (ICRC), St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic





Outline

Temporal Interference (TI): Epilepsy as a model

- Preliminary work in rodents and scaling TI to humans
- Clinical Temporal Interference
- Tremor and Parkinson's disease
- □ Clinical TI of Peripheral nerves
 - Hypoglossal nerve
 - Vagus Nerve
- Conclusions

The Problem



The Problem



increase explorable tissue

decrease resected tissue

The Solution



State-of-the-Art Engineering: non-invasive interferential electric fields State-of-the-Art Clinical Neuroscience: deep brain implants for seizure identification and control

The Solution



State-of-the-Art Engineering: non-invasive interferential electric fields complete focal/position control

State-of-the-Art Clinical Neuroscience: deep brain implants for seizure identification and control

Complete Non-invasive Deep Brain Stimulation in Epilepsy





<u>**T**</u>emporal <u>I</u>nterference (TI) Stimulation

Preliminary Results: Efficacy



B Excitatory Stimulation



50 HZ
and the second state of the state of the second s
No standard evoked

Classic Intracranial f = 50 Hz



Preliminary Results: Efficacy



B Excitatory Stimulation



Classic Intracranial f = 130 Hz



C Inhibitory Stimulation (HFS)



Preliminary Results: Efficacy







Outline

Temporal Interference (TI): Epilepsy as a model

Preliminary work in rodents and scaling TI to humans

Clinical Temporal Interference

- Tremor and Parkinson's disease
- Clinical TI of Peripheral nerves
 - Hypoglossal nerve
 - Vagus Nerve
- Conclusions

Temporal Interference Stimulation (TIS) - principle

- Subject specific modelling of e-fields and electrode positions



Temporal Interference Stimulation (TIS) of subthalamic nucleus (STN) Pilot measurement – 1st patient

Parkinson's disease patient

- male, 64 years, right-handed
- Disease duration 14 years, dominant side right
- With freezings, LED = 1385, UPDRS = 41
- Indicated to STN-DBS, Medtronic Percept IPG, Directional Leads B33005
- Externalized leads, LFP recording, medication OFF state



Lead localization



Orange – motor, blue – associative, yellow – limbic part of STN

Temporal Interference Stimulation (TIS)

- Two stimulation pairs on scalp, high frequency carriers
 - f1 = 9000 Hz, f2 = 9130 Hz, Δf = 130 Hz
 - Stimulation target: position of L1 contact
- LFP recording from externalized leads, fs = 25kHz, Cz scalp reference, recalculated to bipolar L0L1, L1L2, L2L3 (R0R1, R1R2, R2R3)



Note that magnitude of interference artifact differs across bipolar contacts on lead. It means we are able to focus the stimulation also in subcortical regions.

LFP recording, beta power analysis

- fs = 25kHz, Cz scalp reference, recalculated to bipolar
- analysis of LOL3 signal with focus on beta peak power

Comparison of oscillatory components of power spectrum between baseline, conventional DBS stimulation and non-invasive temporal interference stimulation

- Baseline resting state, 2 minutes, OFF medication
- Rest after DBS, 2 mins of recording immediately after 3 mins of stimulation of L1L2, 130Hz, 90us, 2V
- Rest after TIS, 2 mins of recording immediately after 3 mins of stimulation targeted L1, 130 Hz



Note that beta power peak at 26.5Hz is the highest in baseline condition and falls after DBS or TIS stimulation – evaluated after-effect of stimulation. Between DBS and TIS session was approx. 30 minutes pause.

Temporal Interference Stimulation (TIS) of subthalamic nucleus (STN) Pilot measurement – 2nd patient

- Parkinson's disease patient
- male, 53 years, right-handed
- Dominant side left
- Indicated to STN-DBS, Abbott Infinity IPG, Directional Leads 6172
- Externalized leads, LFP recording, medication OFF state



Lead localization



Orange – motor, blue – associative, yellow – limbic part of STN

Temporal Interference Stimulation (TIS)

- Two stimulation pairs on scalp, high frequency carriers
 - f1 = 9000 Hz, f2 = 9130 Hz, Δf = 130 Hz
 - Stimulation target: position of R1 contact
- LFP recording from externalized leads, fs = 25kHz, Cz scalp reference, recalculated to bipolar L0L1, L1L2, L2L3 (R0R1, R1R2, R2R3)



Note: Unfortunately, no clear difference in envelope amplitude between bipolar contacts

LFP recording, beta power analysis

- fs = 25kHz, Cz scalp reference, recalculated to bipolar
- analysis of R1R2 signal with focus on beta peak power

Comparison of oscillatory components of power spectrum between baseline, noninvasive temporal interference stimulation and conventional DBS stimulation

- Baseline resting state, 2 minutes, OFF medication
- Rest after TIS, 2 mins of recording immediately after 3 mins of stimulation targeted R1, 130 Hz
- Rest after DBS, 2 mins of recording immediately after 3 mins of stimulation of R1R2, 130Hz, 90us, 2V



Note that beta power peak is the highest in baseline condition and falls after TIS and DBS stimulation – evaluated after-effect of stimulation. Between TIS and DBS session was approx. 20 minutes pause.









Outline

Temporal Interference (TI): Epilepsy as a model

Preliminary work in rodents and scaling TI to humans

- **Clinical Temporal Interference**
- Tremor and Parkinson's disease
- Clinical TI of Peripheral nerves
 - Hypoglossal nerve
 - Vagus Nerve
- Conclusions

Clinical Temporal Interference



Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Vagus Nerve Phrenic Nerve Hypoglossal Nerve

implantable stimulator

Clinical Temporal Interference



transcutaneous TI



• Normal airflow with no pathological obstruction due to tongue collapse

• Hypoglossal nerve is responsible for tongue tonus



Healthy participant

Obstructive Sleep Apnea (OSA)



• For the **1 Billion people** with obstructive sleep apnea (OSA), CPAP is the standard of care

Loud, Uncomfortable, Infection Risk, Massive Recalls, Poor Compliance



• Hypoglossal nerve stimulation is the standard surgical treatment for OSA



 Non-invasive stimulation is challenging but would avoid surgical procedure and tongue collapse during the night for OSA patients Control



• With **no stimulation**, **no tongue tonus** and protrusion will be induced

 During an OSA event, the direct stimulation of the hypoglossal nerve will prevent tongue collapse



 Unilateral nerve stimulation only induces a partial lateral tongue protrusion

 The stimulation amplitude needed to induce a tongue tonus with unilateral TI is high and induce tingling on the skin



 Bilateral nerve stimulation induces a complete central tongue protrusion

Diminution of stimulation amplitude of about 40%, reducing tingling sensation for a same stimulation output



• Crossed TI design for optimal hypoglossal nerve targeting

- High-frequency carriers to reduce tingling sensation on the skin when applying the bTI stimulation
- **Bilateral TI** with both hypoglossal nerve stimulation at $\Delta f = 50$ Hz





bTI =50Hz, 0.5s ON / 2s OFF

- O₂ saturation is a direct readout of apneas and hypopneas
- Apnea Hypopnea Index (AHI) is calculated overnight and a low AHI is correlated with a good sleep



Overnight polysomnogram

- bTI stimulation efficiently decreases the number of apneas during the night and reduces overnight AHI (~ 60% reduction in women)
- High sex dependency, men hypoglossal nerves are more difficult to depolarize using electrical stimulation
• Device downsizing





• FDA designation "Breakthrough Device"

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has received the above submission requesting designation as a Breakthrough Device. The proposed indications for use includes "The treatment of adult patients with a BMI<35 with moderate to severe OSA (AHI 15-50) who fail or do not tolerate PAP/oral appliances.." We are pleased to inform you that your device and proposed indication for use meet the criteria and have been granted designation as a Breakthrough Device. Please refer to the FDA guidance document entitled "Breakthrough Devices Program", for more information regarding the program, available at https://www.fda.gov/media/108135/download.

We recommend you review the FDA guidance document for the Breakthrough Devices Program referenced above for the available mechanisms for obtaining feedback from the Agency on device development for designated breakthrough devices. When submitting any new requests, please reference Q230334. Any new submission should be provided as an eCopy, it should include the FDA reference number for this submission, and should be submitted to the following address:

Of the 760 devices given Breakthrough Designation since the program started in 2015, only 7 have been under the ENT category and 0 for Sleep.

Outline

Temporal Interference (TI): Epilepsy as a model

Preliminary work in rodents and scaling TI to humans

- **Clinical Temporal Interference**
- Tremor and Parkinson's disease
- Clinical TI of Peripheral nerves
 - Hypoglossal nerve
 - Vagus Nerve

Conclusions

Vagus nerve stimulation (VNS) is an alternative treatment in pharmacoresistant epilepsy.



implantable VNS

Vagus nerve stimulation (VNS) is an alternative treatment in pharmacoresistant epilepsy.





implantable VNS

transcutaneous VNS

Reset. Restore. Relieve.™



transcutaneous TI VNS



transcutaneous TI VNS





implantable VNS



Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Arrangements of electrodes are placed on the skin above the vagus nerve and implant



Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Arrangements of electrodes are placed on the skin above the vagus nerve and implant





Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Arrangements of electrodes are placed on the skin above the vagus nerve and implant







Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Arrangements of electrodes are placed on the skin above the vagus nerve and implant



) battery replacement allows direct access to electrodes on the vagus

Connections from electrodes on the vagus to our recording equipment...





Connections from electrodes on the skin to our TI and transcutaneous stimulation...



Hamdi et al., *Operative Neurosurgery*, 18, 5, 487–495 (2020)



Arrangements of electrodes are placed on the skin above the vagus nerve and implant





access to electrodes on the vagus

New stimulator is replaced when we finish





Poor depth with Transcutaneous Excellent depth with TI Transcutaneous



New stimulator is replaced when we finish





















MicroRegulator



Outline

Temporal Interference (TI): Epilepsy as a model

Preliminary work in rodents and scaling TI to humans

- **Clinical Temporal Interference**
- Tremor and Parkinson's disease
- **Clinical TI of Peripheral nerves**
 - Hypoglossal nerve
 - Vagus Nerve
- **Conclusions**



State-of-the-Art Engineering: non-invasive interferential electric fields State-of-the-Art Clinical Neuroscience: deep brain implants for seizure identification and control



Complete Non-invasive Deep Brain Stimulation in Epilepsy

Team



Funding



European Research Council





Postdocs







Dr. Florian Missey

Dr. Petra Ondráčková

Byun

Dr. Alexandr Dr. Claudia Otahal Lubrano







Pavel Tomíček







Mariane Silva

Collaborators



EMORY UNIVERSITY UNIVERSITY OF CALIFORNIA



Imperial College London



Dr. Mary

Donahue







Dr. Malin Ejneby

Jan Trajlinek

Ondřej Studnička



Eva

Jouval

Děkuji za pozornost







Preliminary Results: Focality





Standard TI



















Preliminary Results: Focality







Standard TI

Preliminary Results: Focality



Standard TI

Patent EP 21306447 - DEEP BRAIN STIMULATION SYSTEM

Focality in NHPs











Target: superior colliculus







Target-Normalized Field







f1 = 1950|2050 Hz **f3** = 5950|6050 Hz **f2** = 3950|4050 Hz **f4** = 7950|8050 Hz




















C1	
C2	
S	







S	_

......

C1

C2

 $\gamma \parallel$

S







